Q-Line Biotech (NSE:QLINE) Total Liabilities: ₹2,655 Mil (As of Mar. 2025)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Total Liabilities?

Q-Line Biotech NSE:QLINE -5.15% 12 Total Liabilities is ₹2,655 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's Total Liabilities for the quarter that ended in Mar. 2025 was ₹2,655 Mil.

Q-Line Biotech's quarterly Total Liabilities increased from Mar. 2023 (₹1,242.14 Mil) to Mar. 2024 (₹1,774.32 Mil) and increased from Mar. 2024 (₹1,774.32 Mil) to Mar. 2025 (₹2,655.41 Mil).

Q-Line Biotech's annual Total Liabilities increased from Mar. 2023 (₹1,242.14 Mil) to Mar. 2024 (₹1,774.32 Mil) and increased from Mar. 2024 (₹1,774.32 Mil) to Mar. 2025 (₹2,655.41 Mil).

Q-Line Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Total Liabilities Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Total Liabilities
1,242.14 1,774.32 2,655.41

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Total Liabilities 1,242.14 1,774.32 2,655.41
NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Q-Line Biotech's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1791.432+(824.118+1.8389999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+26.182+11.835)
=2,655

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=4554.859-1899.453
=2,655

Q-Line Biotech's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1791.432+(824.118+1.8389999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+26.182+11.835)
=2,655

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=4554.859-1899.453
=2,655

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹2,655 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Total Liabilities of ₹2,655 Mil as of Mar. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q-Line Biotech and its competitors.
Is Q-Line Biotech's Total Liabilities too high?
Q-Line Biotech's current Total Liabilities is ₹2,655 Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Total Liabilities compare to ABT and SYK?
Q-Line Biotech's Total Liabilities of ₹2,655 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q-Line Biotech and its competitors. Q-Line Biotech's current Total Liabilities is ₹2,655 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Total Liabilities of ₹2,655 Mil. The current Total Liabilities is ₹2,655 Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Total Liabilities is ₹2,655 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price